Integer Holdings Corporation (ITGR) 10-Year Financial Performance & Capital Metrics

ITGR • • Industrial / General

HealthcareMedical DevicesCardiovascular DevicesCardiac Ablation & Electrophysiology

AboutInteger Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.Show more

Revenue $1.72B +10.3%
EBITDA $318M +22.1%
Net Income $120M +32.3%
EPS (Diluted) 3.40 +26.4%
Gross Margin 26.87% +1.6%
EBITDA Margin 18.52% +10.7%
Operating Margin 12.13% +15.5%
Net Margin 6.98% +19.9%
ROE 7.64% +23.8%
ROIC 5.98% +20.8%
Debt/Equity 0.68 -1.7%
Interest Coverage 3.69 +20.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.58%

5Y6.41%

3Y12.02%

TTM9.54%

Profit (Net Income) CAGR

10Y8.01%

5Y4.47%

3Y7.39%

TTM-23.47%

EPS CAGR

10Y4.74%

5Y4.18%

3Y6.69%

TTM-26.23%

ROCE

10Y Avg5.22%

5Y Avg5.9%

3Y Avg6.05%

Latest7.47%

Peer Comparison

Cardiac Ablation & Electrophysiology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BSXBoston Scientific Corporation	139.56B	94.14	75.31	17.61%	13.53%	11.04%	1.9%	0.51
MDTMedtronic plc	123.61B	96.42	26.71	3.62%	13.71%	9.75%	4.19%	0.59
ITGRInteger Holdings Corporation	2.9B	82.74	24.34	10.35%	4.75%	4.98%	3.44%	0.68
ADGMAdagio Medical Holdings, Inc.	18.68M	0.88	-0.25	-10.33%	-199.86%	-270%		0.82
VTAKCatheter Precision, Inc.	3.42M	2.05	-0.31	-4.98%	-23.81%	-269.53%		0.15

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	800.41M	1.08B	1.14B	1.22B	1.26B	1.07B	1.22B	1.33B	1.56B	1.72B
Revenue Growth %	0.16%	0.34%	0.06%	0.07%	0.04%	-0.15%	0.14%	0.09%	0.17%	0.1%
Cost of Goods Sold+	542.29M	737.82M	782.07M	852.35M	903.08M	787.74M	884.11M	984.63M	1.14B	1.26B
COGS % of Revenue	0.68%	0.69%	0.69%	0.7%	0.72%	0.73%	0.72%	0.74%	0.74%	0.73%
Gross Profit+	258.12M	337.68M	354.01M	362.67M	355.01M	285.71M	336.97M	346.65M	411.52M	461.18M
Gross Margin %	0.32%	0.31%	0.31%	0.3%	0.28%	0.27%	0.28%	0.26%	0.26%	0.27%
Gross Profit Growth %	0.11%	0.31%	0.05%	0.02%	-0.02%	-0.2%	0.18%	0.03%	0.19%	0.12%
Operating Expenses+	244.97M	244.76M	228.36M	207.11M	197.38M	165.09M	201.26M	233.97M	248.2M	252.95M
OpEx % of Revenue	0.31%	0.23%	0.2%	0.17%	0.16%	0.15%	0.16%	0.18%	0.16%	0.15%
Selling, General & Admin	98.2M	134.38M	143.07M	142.45M	138.88M	137.21M	141.69M	157.36M	171.47M	184.33M
SG&A % of Revenue	0.12%	0.12%	0.13%	0.12%	0.11%	0.13%	0.12%	0.12%	0.11%	0.11%
Research & Development	52.99M	47.9M	48.85M	48.6M	46.53M	48.47M	51.98M	59.76M	61.97M	53.42M
R&D % of Revenue	0.07%	0.04%	0.04%	0.04%	0.04%	0.05%	0.04%	0.04%	0.04%	0.03%
Other Operating Expenses	93.78M	62.48M	36.44M	16.06M	11.96M	-20.58M	7.58M	16.85M	14.76M	15.2M
Operating Income+	13.15M	92.92M	125.65M	155.56M	157.63M	120.61M	135.71M	112.68M	163.32M	208.24M
Operating Margin %	0.02%	0.09%	0.11%	0.13%	0.13%	0.11%	0.11%	0.08%	0.1%	0.12%
Operating Income Growth %	-0.83%	6.07%	0.35%	0.24%	0.01%	-0.23%	0.13%	-0.17%	0.45%	0.28%
EBITDA+	57.78M	165.79M	206.83M	237.09M	235.53M	199.94M	217.3M	203.57M	260.31M	317.95M
EBITDA Margin %	0.07%	0.15%	0.18%	0.2%	0.19%	0.19%	0.18%	0.15%	0.17%	0.19%
EBITDA Growth %	-0.49%	1.87%	0.25%	0.15%	-0.01%	-0.15%	0.09%	-0.06%	0.28%	0.22%
D&A (Non-Cash Add-back)	44.63M	72.87M	81.18M	81.54M	77.89M	79.32M	81.59M	90.9M	96.99M	109.71M
EBIT	106.92M	155.4M	162.71M	171.62M	169.6M	103.66M	143.06M	130.85M	178.72M	223.23M
Net Interest Income+	-33.51M	-68.33M	-63.97M	-99.31M	-52.55M	-38.22M	-31.63M	-37.27M	-53.37M	-56.37M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	33.51M	68.33M	63.97M	99.31M	52.55M	38.22M	31.63M	37.27M	53.37M	56.37M
Other Income/Expense	-28.85M	-64.76M	-76.39M	-94.44M	-52.44M	-34.41M	-34.65M	-44M	-57.94M	-60.67M
Pretax Income+	-15.7M	28.16M	49.26M	61.12M	105.19M	86.21M	101.06M	68.68M	105.38M	147.56M
Pretax Margin %	-0.02%	0.03%	0.04%	0.05%	0.08%	0.08%	0.08%	0.05%	0.07%	0.09%
Income Tax+	-8.11M	3.29M	-37.83M	14.08M	13.97M	8.95M	8.04M	8.93M	16.24M	26.51M
Effective Tax Rate %	0.48%	0.21%	1.35%	2.75%	0.92%	0.9%	0.96%	0.97%	0.86%	0.81%
Net Income+	-7.59M	5.96M	66.68M	167.96M	96.34M	77.26M	96.81M	66.38M	90.65M	119.9M
Net Margin %	-0.01%	0.01%	0.06%	0.14%	0.08%	0.07%	0.08%	0.05%	0.06%	0.07%
Net Income Growth %	-1.14%	1.78%	10.19%	1.52%	-0.43%	-0.2%	0.25%	-0.31%	0.37%	0.32%
Net Income (Continuing)	-7.59M	24.88M	87.09M	47.03M	91.22M	77.26M	93.02M	59.75M	89.14M	121.05M
Discontinued Operations	0	-18.92M	-20.41M	120.93M	5.12M	0	3.79M	6.63M	1.51M	-1.16M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.29	0.19	2.08	5.15	2.77	2.33	2.80	1.96	2.69	3.40
EPS Growth %	-1.14%	1.66%	9.95%	1.48%	-0.46%	-0.16%	0.2%	-0.3%	0.37%	0.26%
EPS (Basic)	-0.29	0.19	2.12	5.23	2.80	2.35	2.82	1.97	2.72	3.60
Diluted Shares Outstanding	26.36M	30.97M	32.06M	32.6M	33.04M	33.11M	33.26M	33.36M	33.76M	35.65M
Basic Shares Outstanding	26.19M	30.78M	31.4M	32.14M	32.63M	32.84M	32.99M	33.13M	33.32M	33.6M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	574.6M	517.31M	531.91M	416.25M	415.39M	412.94M	452.98M	558.3M	617.67M	671.12M
Cash & Short-Term Investments	82.48M	52.12M	44.1M	25.57M	13.54M	49.21M	17.89M	24.27M	23.67M	46.54M
Cash Only	82.48M	52.12M	44.1M	25.57M	13.54M	49.21M	17.89M	24.27M	23.67M	46.54M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	219.07M	218.01M	194.84M	185.5M	216.75M	198.51M	251.79M	298.25M	317.15M	349.04M
Days Sales Outstanding	99.9	73.99	62.6	55.73	62.88	67.5	75.26	81.77	74.41	74.22
Inventory	252.17M	225.15M	176.74M	190.08M	167.26M	149.32M	155.7M	208.77M	229.1M	247.13M
Days Inventory Outstanding	169.72	111.38	82.49	81.4	67.6	69.19	64.28	77.39	73.09	71.85
Other Current Assets	0	0	106.75M	0	0	0	0	27M	47.74M	28.41M
Total Non-Current Assets+	2.41B	2.32B	2.32B	1.91B	1.94B	1.96B	2.13B	2.24B	2.32B	2.41B
Property, Plant & Equipment	379.49M	372.04M	370.38M	231.27M	288.56M	299.12M	347.15M	400.9M	501.41M	579.57M
Fixed Asset Turnover	2.11x	2.89x	3.07x	5.25x	4.36x	3.59x	3.52x	3.32x	3.10x	2.96x
Goodwill	1.01B	967.33M	990.24M	832.34M	839.62M	859.44M	924.7M	982.19M	1.01B	1.02B
Intangible Assets	984.26M	940.06M	920.39M	812.34M	775.78M	757.22M	807.81M	819.89M	783.15M	778.29M
Long-Term Investments	20.6M	22.8M	20.81M	26.99M	22.26M	27.19M	21.83M	13.89M	11.83M	7.42M
Other Non-Current Assets	6.02M	9.04M	10.47M	3.56M	7.04M	11.55M	22.03M	12.97M	10.59M	15.54M
Total Assets+	2.98B	2.83B	2.85B	2.33B	2.35B	2.37B	2.58B	2.79B	2.94B	3.08B
Asset Turnover	0.27x	0.38x	0.40x	0.52x	0.53x	0.45x	0.47x	0.48x	0.53x	0.56x
Asset Growth %	2.12%	-0.05%	0.01%	-0.18%	0.01%	0.01%	0.09%	0.08%	0.05%	0.05%
Total Current Liabilities+	213.84M	185.22M	209M	164.57M	179.08M	156.19M	159.63M	223.75M	220.97M	227.17M
Accounts Payable	84.36M	77.9M	64.55M	57.19M	64.97M	51.57M	76.86M	110.78M	118.26M	101.5M
Days Payables Outstanding	56.78	38.53	30.13	24.49	26.26	23.9	31.73	41.07	37.73	29.51
Short-Term Debt	29M	31.34M	30.47M	37.5M	45.01M	45.93M	25.11M	29.64M	10.94M	25.66M
Deferred Revenue (Current)	0	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	52.9M	39.03M	64.68M	10.23M	17.04M	10.63M	7.1M	17.91M	16.3M	20.88M
Current Ratio	2.69x	2.79x	2.54x	2.53x	2.32x	2.64x	2.84x	2.50x	2.80x	2.95x
Quick Ratio	1.51x	1.58x	1.70x	1.37x	1.39x	1.69x	1.86x	1.56x	1.76x	1.87x
Cash Conversion Cycle	212.84	146.84	114.96	112.63	104.22	112.79	107.81	118.1	109.77	116.56
Total Non-Current Liabilities+	1.92B	1.92B	1.75B	1.1B	1.02B	944.61M	1.07B	1.15B	1.2B	1.23B
Long-Term Debt	1.69B	1.7B	1.58B	888.01M	777.27M	693.76M	812.88M	907.07M	959.92M	980.15M
Capital Lease Obligations	0	0	0	0	37.11M	37.86M	67.22M	72.06M	82.4M	101.46M
Deferred Tax Liabilities	221.8M	208.58M	140.96M	203.91M	187.98M	182.3M	171.5M	160.67M	143.55M	124.61M
Other Non-Current Liabilities	10.81M	14.69M	26.3M	9.7M	19.16M	30.69M	16.29M	13.38M	16.77M	25.36M
Total Liabilities	2.13B	2.11B	1.95B	1.27B	1.2B	1.1B	1.23B	1.38B	1.42B	1.46B
Total Debt+	1.71B	1.73B	1.61B	925.51M	859.39M	777.55M	905.81M	1.01B	1.05B	1.1B
Net Debt	1.63B	1.68B	1.57B	899.94M	845.86M	728.34M	887.93M	984.5M	1.03B	1.06B
Debt / Equity	2.02x	2.39x	1.80x	0.87x	0.75x	0.61x	0.67x	0.71x	0.69x	0.68x
Debt / EBITDA	29.67x	10.44x	7.78x	3.90x	3.65x	3.89x	4.17x	4.96x	4.04x	3.47x
Net Debt / EBITDA	28.24x	10.12x	7.60x	3.80x	3.59x	3.64x	4.09x	4.84x	3.95x	3.32x
Interest Coverage	0.39x	1.36x	1.96x	1.57x	3.00x	3.16x	4.29x	3.02x	3.06x	3.69x
Total Equity+	850.63M	725.24M	893.38M	1.06B	1.15B	1.27B	1.35B	1.42B	1.52B	1.62B
Equity Growth %	0.39%	-0.15%	0.23%	0.19%	0.09%	0.1%	0.07%	0.05%	0.07%	0.07%
Book Value per Share	32.27	23.42	27.87	32.53	34.88	38.39	40.73	42.49	45.00	45.42
Total Shareholders' Equity	850.63M	725.24M	893.38M	1.06B	1.15B	1.27B	1.35B	1.42B	1.52B	1.62B
Common Stock	31K	31K	32K	33K	33K	33K	33K	33K	33K	34K
Retained Earnings	231.85M	109.09M	176.07M	344.5M	440.26M	517.52M	614.32M	680.7M	771.35M	891.25M
Treasury Stock	-3.1M	-5.83M	-4.65M	-8.13M	-8.81M	0	0	0	0	0
Accumulated OCI	1.37M	-16M	52.18M	33M	19.99M	52.69M	27.19M	5.33M	20.22M	-14.04M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	12.48M	105.53M	149.36M	167.3M	165.36M	181.34M	156.67M	116.38M	180.21M	205.21M
Operating CF Margin %	0.02%	0.1%	0.13%	0.14%	0.13%	0.17%	0.13%	0.09%	0.12%	0.12%
Operating CF Growth %	-0.85%	7.46%	0.42%	0.12%	-0.01%	0.1%	-0.14%	-0.26%	0.55%	0.14%
Net Income	-7.59M	5.96M	66.68M	167.96M	96.34M	77.26M	96.81M	66.38M	90.65M	119.9M
Depreciation & Amortization	44.63M	90.52M	102.8M	88.99M	77.89M	79.32M	81.37M	91.99M	98.84M	111.03M
Stock-Based Compensation	9.38M	8.41M	14.68M	10.47M	9.29M	9.16M	16.18M	21.02M	23.28M	24.77M
Deferred Taxes	-10.3M	-7.35M	-59.21M	61.13M	-10.29M	-6.97M	-10.27M	-17.5M	-9.49M	-14.11M
Other Non-Cash Items	35.67M	13.99M	20.99M	-151.33M	32.25M	6.4M	20.32M	30.34M	29.23M	18.25M
Working Capital Changes	-59.31M	-6M	3.43M	-9.92M	-40.13M	16.16M	-47.74M	-75.85M	-52.3M	-54.62M
Change in Receivables	3.68M	-2.17M	-34.6M	9.29M	-6.98M	38.15M	-17.54M	-41.38M	-21.08M	-24.98M
Change in Inventory	-25.75M	22.17M	-986K	-16.09M	3.72M	18.44M	4.7M	-56.72M	-30.18M	-18.08M
Change in Payables	3.13M	-1.13M	4.89M	-94K	1.89M	-9.05M	19.52M	26.04M	-520K	-16.62M
Cash from Investing+	-473.56M	-63.3M	-47.94M	536.67M	-58.86M	-56.58M	-271M	-200.42M	-163.37M	-195.41M
Capital Expenditures	-44.62M	-58.63M	-47.3M	-44.91M	-48.2M	-51.44M	-53.46M	-74.73M	-119.94M	0
CapEx % of Revenue	0.06%	0.05%	0.04%	0.04%	0.04%	0.05%	0.04%	0.06%	0.08%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-5.55M	-1.65M	681K	1.38M	4.76M	82K	443K	639K	173K	-56.87M
Cash from Financing+	467.91M	-72.15M	-111.67M	-725.08M	-117.93M	-88.58M	81.99M	92.48M	-18.01M	13.32M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-56.25M	-79.16M	-2.44M	-37.02M	3.24M	2.75M	-9.02M	497K	-42.54M	-3.69M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-32.14M	46.9M	102.06M	122.39M	117.16M	129.9M	103.2M	41.65M	60.27M	99.6M
FCF Margin %	-0.04%	0.04%	0.09%	0.1%	0.09%	0.12%	0.08%	0.03%	0.04%	0.06%
FCF Growth %	-1.57%	2.46%	1.18%	0.2%	-0.04%	0.11%	-0.21%	-0.6%	0.45%	0.65%
FCF per Share	-1.22	1.51	3.18	3.75	3.55	3.92	3.10	1.25	1.79	2.79
FCF Conversion (FCF/Net Income)	-1.64x	17.70x	2.24x	1.00x	1.72x	2.35x	1.62x	1.75x	1.99x	1.71x
Interest Paid	0	0	0	0	0	0	24.74M	35.8M	37.7M	54.17M
Taxes Paid	0	0	0	0	0	0	19.65M	11.16M	30.35M	36.47M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1.04%	0.76%	8.24%	17.19%	8.71%	6.38%	7.37%	4.79%	6.17%	7.64%
Return on Invested Capital (ROIC)	0.62%	2.85%	3.88%	5.28%	5.97%	4.53%	4.8%	3.64%	4.95%	5.98%
Gross Margin	32.25%	31.4%	31.16%	29.85%	28.22%	26.62%	27.6%	26.04%	26.45%	26.87%
Net Margin	-0.95%	0.55%	5.87%	13.82%	7.66%	7.2%	7.93%	4.99%	5.83%	6.98%
Debt / Equity	2.02x	2.39x	1.80x	0.87x	0.75x	0.61x	0.67x	0.71x	0.69x	0.68x
Interest Coverage	0.39x	1.36x	1.96x	1.57x	3.00x	3.16x	4.29x	3.02x	3.06x	3.69x
FCF Conversion	-1.64x	17.70x	2.24x	1.00x	1.72x	2.35x	1.62x	1.75x	1.99x	1.71x
Revenue Growth	16.38%	34.37%	5.63%	6.95%	3.55%	-14.68%	13.75%	9.02%	16.85%	10.35%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Cardio And Vascular	143.26M	-	-	-	-	-	-	-	-	949.58M
Cardio And Vascular Growth	-	-	-	-	-	-	-	-	-	-
Cardiac Rhythm Management & Neuromodulation	-	-	-	-	-	-	-	-	-	660.61M
Cardiac Rhythm Management & Neuromodulation Growth	-	-	-	-	-	-	-	-	-	-
Other Markets	-	-	-	-	-	-	-	-	-	106.41M
Other Markets Growth	-	-	-	-	-	-	-	-	-	-
Medical	-	-	-	1.16B	1.2B	1.04B	1.18B	1.33B	1.55B	-
Medical Growth	-	-	-	-	3.24%	-13.48%	13.94%	12.42%	16.83%	-
Non-Medical	-	41.68M	56.97M	52.98M	58.41M	35.46M	38.45M	46.55M	43.33M	-
Non-Medical Growth	-	-	36.68%	-7.01%	10.27%	-39.29%	8.43%	21.04%	-6.90%	-
Cardiac Neuromodulation	356.06M	-	-	-	-	-	-	-	-	-
Cardiac Neuromodulation Growth	-	-	-	-	-	-	-	-	-	-
Advanced Surgical, Orthopaedics, and Portable Medical	243.38M	-	-	-	-	-	-	-	-	-
Advanced Surgical, Orthopaedics, and Portable Medical Growth	-	-	-	-	-	-	-	-	-	-
Electrochem	59.45M	-	-	-	-	-	-	-	-	-
Electrochem Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	401.38M	805.74M	862.29M	687.26M	698.47M	596.8M	671.5M	762.13M	897.43M	938.67M
UNITED STATES Growth	-	100.74%	7.02%	-20.30%	1.63%	-14.56%	12.52%	13.50%	17.75%	4.60%
Rest Of World	199.59M	352.64M	465.88M	319.21M	341.34M	321.74M	372.44M	423.74M	501.25M	516.17M
Rest Of World Growth	-	76.68%	32.11%	-31.48%	6.93%	-5.74%	15.76%	13.78%	18.29%	2.98%
PUERTO RICO	136.9M	159.24M	133.75M	146.5M	154.64M	96.05M	110.16M	114.08M	108.42M	137.06M
PUERTO RICO Growth	-	16.32%	-16.01%	9.53%	5.56%	-37.89%	14.69%	3.55%	-4.96%	26.41%
BELGIUM	62.55M	69.15M	-	-	-	-	-	-	-	-
BELGIUM Growth	-	10.56%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Integer Holdings Corporation (ITGR) has a price-to-earnings (P/E) ratio of 24.3x. This is roughly in line with market averages.

Growth & Financials

Integer Holdings Corporation (ITGR) reported $1.83B in revenue for fiscal year 2024. This represents a 222% increase from $568.8M in 2011.

Integer Holdings Corporation (ITGR) grew revenue by 10.3% over the past year. This is steady growth.

Yes, Integer Holdings Corporation (ITGR) is profitable, generating $86.9M in net income for fiscal year 2024 (7.0% net margin).

Dividend & Returns

Integer Holdings Corporation (ITGR) has a return on equity (ROE) of 7.6%. This is below average, suggesting room for improvement.

Integer Holdings Corporation (ITGR) generated $165.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...